Ultragenyx Pharmaceutical Inc (FRA:UP0)
€ 46.2 -0.4 (-0.86%) Market Cap: 4.31 Bil Enterprise Value: 3.76 Bil PE Ratio: 0 PB Ratio: 13.42 GF Score: 81/100

Q3 2023 Ultragenyx Pharmaceutical Inc Earnings Call Transcript

Nov 02, 2023 / 09:00PM GMT
Release Date Price: €34 (+1.80%)
Operator

Good afternoon and welcome to the Ultragenyx Third Quarter 2023 Financial Results Conference Call. (Operator Instructions). It is now my pleasure to turn the call over to Joshua Higa, Vice President of Investor Relations.

Joshua Higa
Ultragenyx Pharmaceutical Inc. - Director of IR & Corporate Communications

Thank you. We've issued a press release detailing our financial results, which you can find on our website at ultragenyx.com. Joining me on this call are Emil Kakkis, Chief Executive Officer and President; Erik Harris, Chief Commercial Officer; Howard Horn, Chief Financial Officer; Eric Crombez, Chief Medical Officer; Aaron Olsen, Senior Vice President of Corporate Strategy and Finance; and Ted Huizenga, Chief Accounting Officer.

I'd like to remind everyone that during today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties and our actual results may differ materially. Please refer to the risk factors discussed in our latest SEC filings. I'll now turn the call over to Emil.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot